期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 22, 期 11, 页码 1367-1375出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543776.2012.714371
关键词
anti-tumor; calcium phosphate; hybrid nanocomplex; self-assembled nanoparticles; targeted drug delivery; zoledronic acid
The focus of this patent was to manipulate the pharmacokinetic profile of an amino-bisphosphonate (zoledronic acid, ZOL) to make it desirable for antitumor uses. This patent disclosed a unique drug loading strategy that was inspired by gene delivery vehicles based on similar materials (calcium phosphate, CaP). The promise of this drug delivery system (DDS) lies not only in a 44% in vivo inhibition of tumor growth compared with free drug, but also in the low toxicity of the drug which guarantees a dosage regimen with higher doses and longer course of treatment. Also, the disclosed DDS has the potential to be further upgraded. In this patent evaluation, the state of the art in the field of CaP-based drug carrier and the novelty of this invention will be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据